Ann Rheum Dis: Comparing the long-term outcome of a randomized controlled trial of tamoxolphos with mycophenolic acid-induced treatment for lupus nephritis

The study was designed to report a 10-year outcome of a randomized controlled trial using nephrophenol (MMF) or taquemox (TAC) to induce treatment for lupus nephritis (LN)active LN patients treated with MMF or TAC combined with large doses of pernitoneAt the 6th month, the respondent was replaced with thiopental (AZA) therapyThe clinical outcome (acute onset of the kidneys, decreased renal function and death) was assessed for 10 yearsAnalysis of the factors affecting the prognosis through Cox regressionThe urinary protein/creatinine ratio (uPCr) at different points in time was analyzed and the predicted value of the nephrosphere filtration rate (eGFR) for adverse prognosis was assessed by the subjects' working characteristic curve (ROC)150 patients were studied (age 35.5 to 12.8 years)MMF (59%) and TAC (62%; p.0.71) treated patients with similar full kidney response rates79% of patients use AZA maintenance therapyAfter 118.2 to 42 months, 34% and 37% of MMF patients had a proteinuria and nephritis attacks, respectively, compared with 53% and 30% in the TAC group, respectivelyThe cumulative incidence of eGFR decreased by 30% in both groups in 10 years, 4/5 level stoic in stages of chronic kidney disease, or in the compound outcome of death was 33% (p-0.90)The factors associated with renal prognosis are the initial LN (HR 0.12 (0.031-0.39) ;p s 0.01), eGFR (HR 0.98 (0.96-0.99) ;p s 0.008) and 6 months without response (HR 5.18 (1.40-19.1);p .01)ROC analysis showed that at the 18th month uPCr 0.75, eGFR 80mL/min predicted the highest value of kidney prognosislong-term data confirm that TAC as an LN induction treatment is no less than MMFAt 18 months uPCr is 0.75 and eGFR is able to best predict a good outcome for 10 years and is an appropriate target for induction/consolidation therapy